Fifty years ago, President Richard Nixon signed the National Cancer Act into law to restructure the country’s way of dealing with a leading cause of death and suffering. Here, Jeff Allen — president and CEO of Friends of Cancer Research — describes new approaches to accelerate the testing of new drugs, including advanced applications of circulating tumor DNA. Allen describes recent work as “a paradigm shift to bring treatments more efficiently to those that need them.”